Biosimilars
Introduced in the 1980s, biologic medications have since become important tools in modern medicine. However, biologics are expensive, greatly affecting the healthcare budgets of both underdeveloped and developed countries. Fortunately, biosimilars, which are highly similar, reverse-engineered versio...
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
IntechOpen
2022
|
| Subjects: | |
| Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
| LEADER | 02113namaa2200433uu 4500 | ||
|---|---|---|---|
| 001 | doab90326 | ||
| 003 | oapen | ||
| 005 | 20220727 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 220727s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a 9781838819354 | ||
| 020 | |a 9781838819439 | ||
| 020 | |a 9781839681677 | ||
| 020 | |a intechopen.87638 | ||
| 024 | 7 | |a 10.5772/intechopen.87638 |2 doi | |
| 040 | |a oapen |c oapen | ||
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a MKG |2 bicssc | |
| 720 | 1 | |a Feijó Azevedo, Valderilio |4 edt | |
| 720 | 1 | |a Feijó Azevedo, Valderilio |4 oth | |
| 720 | 1 | |a Moots, Robert |4 edt | |
| 720 | 1 | |a Moots, Robert |4 oth | |
| 245 | 0 | 0 | |a Biosimilars |
| 260 | |b IntechOpen |c 2022 | ||
| 300 | |a 1 online resource (106 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
| 520 | |a Introduced in the 1980s, biologic medications have since become important tools in modern medicine. However, biologics are expensive, greatly affecting the healthcare budgets of both underdeveloped and developed countries. Fortunately, biosimilars, which are highly similar, reverse-engineered versions of existing biological medicines and their active ingredients, are now available as more affordable options for patients treated with biologics. This book discusses biosimilars with chapters on clinical trials, regulation, pharmacovigilance, and the interchangeability of biosimilars with biologics. It also addresses future trends in the biosimilars market. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/3.0/ |2 cc |u https://creativecommons.org/licenses/by/3.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Pharmacology |2 bicssc | |
| 653 | |a Pharmacology | ||
| 793 | 0 | |a DOAB Library. | |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/90326 |7 0 |z Open Access: DOAB: description of the publication |
| 856 | 4 | 0 | |u https://mts.intechopen.com/storage/books/9829/authors_book/authors_book.pdf |7 0 |z Open Access: DOAB, download the publication |